托烷司琼对精神分裂症患者听感觉门控P50的影响  

Efficacy of Tropisetron on Auditory Sensory Gating P50 in Patients with Schizophrenia

作　　者：刘磊[1] 刘少文[1] 洪晓虹[1] 张向阳[2] 

机构地区：[1]汕头大学精神卫生中心,广东汕头515063 [2]北京回龙观医院,北京102208

出　　处：《汕头大学医学院学报》2010年第1期32-35,共4页Journal of Shantou University Medical College

摘　　要：目的:探讨托烷司琼对精神分裂症患者听感觉门控P50的影响。方法:服用利培酮的精神分裂症患者(40例)随机分为安慰剂组、小、中、高剂量(托烷司琼5、10、20 mg/d)组,采用配对听觉条件刺激(S1)、测试刺激(S2)范式,观察不同剂量托烷司琼对精神分裂症患者听感觉门控P50的影响,用副反应量表评估用药安全性。结果:①安慰剂组在用药前、后P50抑制差别无统计学意义,小、中剂量组在用药后第1、10 d能明显改善P50抑制,高剂量组在用药第10 d后能明显改善P50抑制,且剂量组间差别有统计学意义(P<0.01),中剂量组优于小剂量组,小剂量组优于高剂量组。②小、中剂量组不良反应轻微,高剂量组有不良反应。结论:托烷司琼能明显改善精神分裂症患者听感觉门控P50,对精神分裂症的神经认知缺陷可能有潜在的治疗作用,且以中剂量为佳。Objective： To explore the efficacy of tropisetron on auditory sensory gating P50 in patients with schizophrenia. Methods： Forty patients with schizophrenia taken risperidone were randomly assigned to placebo group, the small dose（tropisetron 5 mg/d）group, the moderate dose（tropisetron 10 rag/d）group and the high dose （tropisetron 20 mg/d） group. By paired clicks auditory condition and testing stimuluting paradigm, the efficacy of different doses of tmpisetron on auditory sensory gating P50 in patients with schizophrenia was observed. Safety was evaluated by Treatment Emergent Symptom Scale. Results： The placebo group had no significant influence on P50 inhibition. Five rag and 10 mg/d dose of tropisetron could improve P50 inhibition after the first day and the tenth day drug administration than baseline, 20 mg/ d dose of tropisetron could improve P50 inhibition after the tenth day administration. There were significant differences among groups, 10 mg/d was better than 5 mg/d, 5 mg/d was better than 20 mg/d. The adverse effects were mild in 5 and 10 mg/d doses, the 20 mg/d dose had adverse effects . Conclusion： Tmpisetron can improve the auditory sensory gating P50 in patients with schizophrenia and may be a passible therapeutic effect for neurocognitive deficits for schizophrenia, 10 mg/d may be a better dosage.

关 键 词：托烷司琼 精神分裂症 听感觉门控P50 

分 类 号：R749.3[医药卫生—神经病学与精神病学]